Relapesed/Refractory (MAGNIFY)
- Result Type
- clinical trial
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
You are viewing results from Research and Clinical Trials.
2results found for:
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
Status: Active, Not Recruiting
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active, Recruiting
Check-ups, screenings and sick visits for adults and children.
Expertise and advanced technologies in all areas of medicine.
For serious accidents, injuries and conditions that require immediate medical care.
After-hours, weekend and holiday services.
Convenient walk-in care clinics for your non-urgent health needs.
We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences